Skip to main content
SpringerLink
Log in

Antifibrinolytics: Indications and Precautions

  • Chapter
  • First Online:
Nonmalignant Hematology

  • 1639 Accesses

Abstract

A very important regulator of hemostasis is the fibrinolytic pathway, which is activated concurrently with platelet aggregation, with thrombin production, and ultimately with fibrin generation. Fibrinolysis is influenced by many factors including clot burden, the concentration of coagulation factors, and the local environment. In certain nonphysiological conditions, such as trauma and surgery, there is an increased propensity toward fibrinolysis related to the release of tissue plasminogen activator (tPA) at the site of injury which may result in increased bleeding (Bluth and Kashuk 2011; Cardenas et al. 2014). Patients with hereditary bleeding disorders such as Von Willebrand disease (VWD) and hemophilia also have a tendency to bleed that is partly influenced by increased activity of the fibrinolytic pathway (Matsumoto et al. 2013).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Bibliography

  • Bayer Health Care. Trasylol (aprotinin injection). US prescribing information. West Haven (CT): Bayer Pharmaceuticals Corporation; 2006.

    Google Scholar 

  • Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost. 2001;86(2):714–5.

    CAS  PubMed  Google Scholar 

  • Binette TM, Taylor FB, Peer G, Bajzar L. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon. Blood. 2007;110(9):3168–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bluth MH, Kashuk JL. Mechanistic links in trauma-induced coagulopathy: a tale of two cities. Ann Surg. 2011;254(1):20–1.

    Article  PubMed  Google Scholar 

  • Cardenas JC, Matijevic N, Baer LA, Holcomb JB, Cotton BA, Wade CE. Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients. Shock. 2014;41(6):514–21.

    Article  CAS  PubMed  Google Scholar 

  • Gungorduk K, Yıldırım G, AsıcıoÄŸlu O, Gungorduk OC, Sudolmus S, Ark C. Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study. Am J Perinatol. 2011;28(3):233–40.

    Google Scholar 

  • Gungorduk K, AsıcıoÄŸlu O, Yıldırım G, Ark C, TekirdaÄŸ AÄ°, Besımoglu B. Can intravenous injection of tranexamic acid be used in routine practice with active management of the third stage of labor in vaginal delivery? A randomized controlled study. Am J Perinatol. 2013;30(5):407-13.

    Google Scholar 

  • Clover Pharmaceuticals Corp. Amicar (aminocaproic acid). Marietta, 2012.

    Google Scholar 

  • Davis A, Walsh M, Mccarthy P, et al. Tranexamic acid without prophylactic factor replacement for prevention of bleeding in hereditary bleeding disorder patients undergoing endoscopy: a pilot study. Haemophilia. 2013;19(4):583–9.

    Article  CAS  PubMed  Google Scholar 

  • Dewan Y, Komolafe EO, Mejía-Mantilla JH, et al. CRASH-3 – tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial. Trials. 2012;13:87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dietrich W, Ebell A, Busley R, Boulesteix AL. Aprotinin and anaphylaxis: analysis of 12,403 exposures to aprotinin in cardiac surgery. Ann Thorac Surg. 2007;84(4):1144–50.

    Article  PubMed  Google Scholar 

  • Eriksson O, Kjellman H, Pilbrant A, Schannong M. Pharmacokinetics of tranexamic acid after intravenous administration to normal volunteers. Eur J Clin Pharmacol. 1974;7(5):375–80.

    Article  CAS  PubMed  Google Scholar 

  • Federici AB, Sacco R, Stabile F, Carpenedo M, Zingaro E, Mannucci PM. Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases. Haemophilia. 2000;6(2):71–7.

    Article  CAS  PubMed  Google Scholar 

  • Fergusson DA, Hébert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358(22):2319–31.

    Article  CAS  PubMed  Google Scholar 

  • Flight S, Johnson L, Trabi M, et al. Comparison of textilinin-1 with aprotinin as serine protease inhibitors and as antifibrinolytic agents. Pathophysiol Haemost Thromb. 2005;34(4–5):188–93.

    CAS  PubMed  Google Scholar 

  • Fraser IS, Porte RJ, Kouides PA, Lukes AS. A benefit-risk review of systemic haemostatic agents: part 1: in major surgery. Drug Saf. 2008;31(3):217–30.

    Article  CAS  PubMed  Google Scholar 

  • Health Canada's response to the final report of expert advisory panel on Trasylol® (aprotinin). (2011, September 15). Retrieved 1 Apr 2015.

    Google Scholar 

  • Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2011;3:CD001886.

    PubMed  Google Scholar 

  • Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL. The dose-response relationship of tranexamic acid. Anesthesiology. 1995;82(2):383–92.

    Article  CAS  PubMed  Google Scholar 

  • Howell N, Senanayake E, Freemantle N, Pagano D. Putting the record straight on aprotinin as safe and effective: results from a mixed treatment meta-analysis of trials of aprotinin. J Thorac Cardiovasc Surg. 2013;145(1):234–40.

    Article  CAS  PubMed  Google Scholar 

  • Kouides PA, Byams VR, Philipp CS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol. 2009;145(2):212–20.

    Article  CAS  PubMed  Google Scholar 

  • Kriplani A, Kulshrestha V, Agarwal N, Diwakar S. Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. J Obstet Gynaecol. 2006;26(7):673–8.

    Article  CAS  PubMed  Google Scholar 

  • Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116(4):865–75.

    Article  PubMed  Google Scholar 

  • LYSTEDA ®. Full Prescribing Information. Parsippany: Ferring Pharmaceuticals. Atlanta, GA: Mikart, Inc.; 2013.

    Google Scholar 

  • Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354(4):353–65.

    Article  CAS  PubMed  Google Scholar 

  • Mannucci PM. Hemostatic drugs. N Engl J Med. 1998;339(4):245–53.

    Article  CAS  PubMed  Google Scholar 

  • Matsumoto T, Nogami K, Shima M. Simultaneous measurement of thrombin and plasmin generation to assess the interplay between coagulation and fibrinolysis. Thromb Haemost. 2013;110(4):761–8.

    Article  CAS  PubMed  Google Scholar 

  • Menkis AH, Martin J, Cheng DC, et al. Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011. Innovations (Phila). 2012;7(4):229–41.

    Article  PubMed  Google Scholar 

  • Millers EK, Johnson LA, Birrell GW, et al. The structure of human microplasmin in complex with textilinin-1, an aprotinin-like inhibitor from the Australian brown snake. PLoS One. 2013;8(1):e54104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mitra B, Mazur S, Cameron PA, et al. Tranexamic acid for trauma: filling the ‘GAP’ in evidence. Emerg Med Australas. 2014;26(2):194–7.

    Article  PubMed  Google Scholar 

  • Moor AC, Dubbelman TM, Vansteveninck J, Brand A. Transfusion-transmitted diseases: risks, prevention and perspectives. Eur J Haematol. 1999;62(1):1–18.

    Article  CAS  PubMed  Google Scholar 

  • Patatanian E, Fugate SE. Hemostatic mouthwashes in anticoagulated patients undergoing dental extraction. Ann Pharmacother. 2006;40(12):2205–10.

    Article  CAS  PubMed  Google Scholar 

  • Seligsohn U. Treatment of inherited platelet disorders. Haemophilia. 2012;18 Suppl 4:161–5.

    Article  PubMed  Google Scholar 

  • Shakur H, Elbourne D, Gülmezoglu M, et al. The WOMAN trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials. 2010a;11:40.

    Google Scholar 

  • Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010b;376(9734):23–32.

    Article  CAS  PubMed  Google Scholar 

  • Silva MM, Thelwell C, Williams SC, Longstaff C. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue-type plasminogen activator. J Thromb Haemost. 2012;10(11):2354–60.

    Article  CAS  PubMed  Google Scholar 

  • Simpson ML, Goldenberg NA, Jacobson LJ, Bombardier CG, Hathaway WE, Manco-Johnson MJ. Simultaneous thrombin and plasmin generation capacities in normal and abnormal states of coagulation and fibrinolysis in children and adults. Thromb Res. 2011;127(4):317–23.

    Article  CAS  PubMed  Google Scholar 

  • Thelwell C, Longstaff C. The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1. J Thromb Haemost. 2007;5(4):804–11.

    Article  CAS  PubMed  Google Scholar 

  • Tubbs RR, Benjamin SP, Dohn DE. Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis. Case report. J Neurosurg. 1979;51(1):94–7.

    Article  CAS  PubMed  Google Scholar 

  • Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood. 2009;113(15):3406–17.

    Article  CAS  PubMed  Google Scholar 

  • Van Renterghem D, De Reuck J, Schelstraete K, Elinck W, Van der Straeten M. Epsilon amino caproic acid myopathy: additional features. Clin Neurol Neurosurg. 1984;86(3):153–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Rochester General Hospital, Rochester, NY, USA

    Munjid Al Harthy

  2. Department of Hematology, Rochester General Hospital, 1425 Portland Avenue, Rochester, NY, 14621, USA

    Peter Kouides

Authors
  1. Munjid Al Harthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Kouides
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Kouides .

Editor information

Editors and Affiliations

  1. Cancer Treatment Centers of America, Department of Hematology and Bone Marrow Transplantion, Zion, Illinois, USA

    Syed A. Abutalib

  2. Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts, USA

    Jean M. Connors

  3. Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

    Margaret V. Ragni

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Al Harthy, M., Kouides, P. (2016). Antifibrinolytics: Indications and Precautions. In: Abutalib, S., Connors, J., Ragni, M. (eds) Nonmalignant Hematology. Springer, Cham. https://doi.org/10.1007/978-3-319-30352-9_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-30352-9_28

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-30350-5

  • Online ISBN: 978-3-319-30352-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation